CUMBERLAND, R.I.--(BUSINESS WIRE)--Neurotech Pharmaceuticals, Inc., a private biotech company focused on developing transformative therapies for chronic eye diseases, announced that the U.S. Food and ...

John A. Moran Eye Center retinal specialist and researcher Paul S. Bernstein, MD, PhD, diagnosed John Ehrman with a rare eye disease known as Macular Telangiectasia Type 2 (MacTel) in 2014. The ...

Charles C. Wykoff, MD, PhD, Retinal Consultants of Texas, spoke to the current state of research on revakinagene taroretcel in macular telangiectasia type 2 (MacTel), as well as the importance of ...

A woman losing her vision. How experts can slow down the effects of a rare eye disease.

The FDA approved revakinagene taroretcel (Encelto) as the first treatment for adults with idiopathic macular telangiectasia (MacTel) type 2, Neurotech Pharmaceuticals announced on Thursday. A rare, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Macular telangiectasia type 2 (MacTel) is a rare, ...

Please provide your email address to receive an email when new articles are posted on . Macular telangiectasia type 2 (MacTel) is a rare, retinal, neurodegenerative, bilateral disease that causes a ...

DURHAM, N.C. (WTVD) -- Duke Eye Center has become the first academic medical center in the country to implant a new cell-based gene therapy for a rare eye disease called MacTel. This procedure offers ...

The approval of revakinagene taroretcel (Encelto; Neurotech) addresses a significant unmet need for patients with macular telangiectasia type 2 (MacTel), clinical investigator Charles C. Wykoff, MD, ...